European equities traded in the US as American depositary receipts were tracking lower late Friday morning, declining 0.47% to 1,520.35 on the S&P Europe Select ADR Index, which is down 1.5% for the week.
From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and biopharmaceutical company Cellectis (CLLS), which advanced 9.4% and 1.5%, respectively. They were followed by accommodations booking company trivago (TRVG) and internet advertising company Criteo (CRTO), which increased 1.2% and 1.1%, respectively.
The decliners from continental Europe were led by biotech firm Evaxion (EVAX) and internet browser company Opera (OPRA), which lost 6.9% and 2.9%' respectively. They were followed by software firm SAP (SAP) and semiconductor company Sequans Communications (SQNS), which dropped 1.6% and 1.3%, respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and insurance company Prudential (PUK), which rose 2.2% and 1.9%, respectively. They were followed by software company Endava (DAVA) and tobacco producer British American Tobacco (BTI), which were up 1.4% and 0.6%, respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and biotech company Trinity Biotech (TRIB), which fell 9.1% and 4.5%, respectively. They were followed by financial services companies Lloyds Banking Group (LYG) and Barclays (BCS), which were down 3.2% and 2.4%, respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.